Strategic Asset Sale Zealand Pharma's recent sale of rights to their obesity drug petrelintide to Roche for up to 5.3 billion dollars indicates a successful exit strategy and potential for collaboration or licensing opportunities with larger pharma companies seeking innovative peptide therapies.

Focus on Obesity and Rare Diseases With ongoing development of petrelintide for obesity and diabetes, and a pipeline centered on obesity, chronic inflammation, and rare diseases, there are significant opportunities to partner or supply complementary technologies and services in these high-growth therapeutic areas.

Leadership Expansion Recent strategic hires, including a new Chief Scientific Officer and a Chief Development Officer focused on obesity, show Zealand's commitment to innovation and pipeline acceleration, making them a potential partner for advanced research tools, scientific collaboration, and clinical development services.

Growth and Funding Although currently generating modest revenue between 25 and 50 million dollars, Zealand Pharma's recent funding and strong R&D focus suggest investment opportunities in supportive technologies, manufacturing capabilities, and commercialization strategies to help scale their promising therapies.

Technology and Data Tools Zealand Pharma utilizes advanced tech stacks like Power BI, Microsoft Azure, and SQL, indicating a data-driven approach; there is potential to offer data analytics, cloud services, or real-time monitoring solutions to enhance their clinical and operational workflows.